Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Antibiotic aggregator

How Cubist needs to execute after buying antibiotics plays Optimer, Trius

Cubist Pharmaceuticals Inc. is buying a pair of antibiotics companies to gain two compounds as revenue drivers to fill the gap between Cubicin daptomycin and the company's Phase III pipeline. Cubist's task now is to wrestle scrips away from lower priced generics by convincing hospitals of the value of Optimer Pharmaceuticals Inc.'s Dificid fidaxomicin and, if approved next year, Trius Therapeutics Inc.'s tedizolid.

With an existing U.S. sales force and plans to establish one in Europe, Cubist seized an opportunity last week to gain two products it believes line up well with the company's marketing expertise.

"These are going to be niche-strategy drugs that may be expensive relative to their competitors, which are mainly generics that hospitals will use as frequently as they can because of economic pressures. But we are very experienced in dealing with this market," said Robert Perez, president and COO of Cubist.

"The answer is finding the appropriate patients where you can make the argument that you not only have better

Read the full 1628 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE